OBJECTIVES: Controversy persists on the use of adjuvant radiotherapy (RT) in patients with retroperitoneal sarcoma (RPS). High-grade disease is known to be associated with decreased local control and overall survival (OS). Because RT has proven beneficial for local control and OS in patients with high-grade extremity soft tissue sarcoma, we evaluated the efficacy of adjuvant RT in high-grade RPS. METHODS: The Surveillance, Epidemiology, and End Results database was used to identify patients with pathology-confirmed RPS from 1973 to 2010. Clinical characteristics and outcomes were analyzed. RESULTS: Of 480 total patients, 144 (30.0%) received postoperative radiation. Patients who received adjuvant RT had improved median OS (36 mo) compared with those who did not (27 mo, hazard ratio [HR]=0.79, P=0.023). On multivariate analysis the use of adjuvant RT (HR=0.80; 95% confidence interval [CI], 0.65-0.98; P=0.029), male sex (HR=1.32; 95% CI, 1.10-1.59; P=0.003), age above 65 years (HR=1.38; 95% CI, 1.15-1.67; P=0.001), and increasing the Surveillance, Epidemiology, and End Results historical stage (HR=1.46; 95% CI, 1.21-1.76; P<0.001) were all prognostic factors for OS. CONCLUSIONS: In a large retrospective analysis, postoperative RT improved OS in high-grade RPS patients. As such, adjuvant RT should be strongly considered in all patients with high-grade RPS. The optimal timing of RT relative to surgery requires further study.
OBJECTIVES: Controversy persists on the use of adjuvant radiotherapy (RT) in patients with retroperitoneal sarcoma (RPS). High-grade disease is known to be associated with decreased local control and overall survival (OS). Because RT has proven beneficial for local control and OS in patients with high-grade extremity soft tissue sarcoma, we evaluated the efficacy of adjuvant RT in high-grade RPS. METHODS: The Surveillance, Epidemiology, and End Results database was used to identify patients with pathology-confirmed RPS from 1973 to 2010. Clinical characteristics and outcomes were analyzed. RESULTS: Of 480 total patients, 144 (30.0%) received postoperative radiation. Patients who received adjuvant RT had improved median OS (36 mo) compared with those who did not (27 mo, hazard ratio [HR]=0.79, P=0.023). On multivariate analysis the use of adjuvant RT (HR=0.80; 95% confidence interval [CI], 0.65-0.98; P=0.029), male sex (HR=1.32; 95% CI, 1.10-1.59; P=0.003), age above 65 years (HR=1.38; 95% CI, 1.15-1.67; P=0.001), and increasing the Surveillance, Epidemiology, and End Results historical stage (HR=1.46; 95% CI, 1.21-1.76; P<0.001) were all prognostic factors for OS. CONCLUSIONS: In a large retrospective analysis, postoperative RT improved OS in high-grade RPS patients. As such, adjuvant RT should be strongly considered in all patients with high-grade RPS. The optimal timing of RT relative to surgery requires further study.
Authors: J Jakob; A Gerres; U Ronellenfitsch; L Pilz; M Wartenberg; B Kasper; H-R Raab; P Hohenberger Journal: Chirurg Date: 2018-01 Impact factor: 0.955
Authors: B T Turner; L Hampton; D Schiller; L A Mack; C Robertson-More; H Li; M L Quan; A Bouchard-Fortier Journal: Curr Oncol Date: 2019-12-01 Impact factor: 3.677
Authors: A Montero; M Nuñez; O Hernando; E Vicente; R Ciervide; D Zucca; E Sanchez; M López; Y Quijano; M Garcia-Aranda; R Alonso; J Valero; X Chen; B Alvarez; P Fernandez-Leton; C Rubio Journal: Rep Pract Oncol Radiother Date: 2020-06-09
Authors: Thomas Malinka; Maxim Nebrig; Fritz Klein; Johann Pratschke; Marcus Bahra; Andreas Andreou Journal: BMC Surg Date: 2019-06-10 Impact factor: 2.102
Authors: Rick L M Haas; Sylvie Bonvalot; Rosalba Miceli; Dirk C Strauss; Carol J Swallow; Peter Hohenberger; Frits van Coevorden; Piotr Rutkowski; Dario Callegaro; Andrew J Hayes; Charles Honoré; Mark Fairweather; Rebecca Gladdy; Jens Jakob; Milena Szacht; Marco Fiore; Peter W Chung; Winan J van Houdt; Chandrajit P Raut; Alessandro Gronchi Journal: Cancer Date: 2019-01-02 Impact factor: 6.860